Related Experiment Video
Updated: Jan 20, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.9K
An Innovative Platform to Analyze Heart Failure Biomarkers in Saliva
A Martínez-García1, P García-Ocaña2, S Rodríguez-Suárez2
1Group of Research and Innovation in Biomedical Informatics, Biomedical Engineer and Health Economy, Institute of Biomedicine of Seville, IBiS/"Virgen del Rocío" University Hospital /CSIC/University of Seville, Spain.
Studies in Health Technology and Informatics
|August 24, 2019
Summary
This study introduces a new biosensor method for early detection of heart failure (HF) complications. Salivary TNF-alpha levels correlate with weight gain, potentially predicting HF decompensation.
Area of Science:
- Biomedical Engineering
- Cardiology
- Biomarker Discovery
Background:
- Heart failure (HF) management requires early detection of complications.
- Existing methods for monitoring HF decompensation can be invasive or delayed.
- Novel, non-invasive biomarkers are needed for timely intervention.
Purpose of the Study:
- To present a biosensor-based methodology for early detection of HF complications.
- To analyze specific biomarkers in saliva for HF monitoring.
- To validate the findings through a pilot study in clinical settings.
Main Methods:
- Development of a biosensor within the HEARTEN project for saliva analysis.
- Conducting a pilot study across two European hospitals (Spain and Italy).
- Measuring levels of specific biomarkers, including TNF-alpha, in patient saliva samples.
Main Results:
- A direct correlation was established between salivary TNF-alpha levels and patient weight.
- Weight gain in HF patients was identified as a predictor of decompensation.
- TNF-alpha emerged as a potential novel biomarker for HF decompensation events.
Conclusions:
- The developed biosensor methodology offers a promising approach for early HF complication detection.
- Salivary TNF-alpha shows potential as a non-invasive biomarker for predicting HF decompensation.
- This approach could significantly improve patient safety and HF management.
More Related Videos
Related Concept Videos
01:29Heart Failure II: Pathophysiology
768
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
720
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
01:22Heart Failure VI: Adjunct Therapies
273
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
01:22Heart Failure Drugs: Diuretics
821
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
01:30Heart Failure V: Medical Management
225
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225